Even though BIRC3 mutation or deletion has been reported in about 3–7% of the CLL cases, its disruption predicts poor prognosis and represents an independent risk factor [37, 38]. This evidence concerns the gene BIRC3 and B-cell chronic lymphocytic leukemia.